Do Glucagon Like Peptide-۱ Receptor Agonists Modify Progression of Primary Glenohumeral Osteoarthritis? A Propensity Score–Matched Evaluation of Shoulder Arthroplasty Incidence
محل انتشار: مجله استخوان و جراحی عمومی، دوره: 14، شماره: 11
سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 25
فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_TABO-14-11_004
تاریخ نمایه سازی: 22 آبان 1405
چکیده مقاله:
Objectives: Glenohumeral osteoarthritis (OA) is a common degenerative condition, and total shoulder arthroplasty (TSA) often represents the definitive treatment for end-stage disease. The use of glucagon-like peptide-۱ receptor agonists (GLP-۱RA) has increased substantially, and recent evidence suggests potential disease-modifying effects and reduced arthroplasty rates in lower-extremity joints. This study evaluated whether GLP-۱RA use is associated with progression from primary shoulder OA to TSA. Methods: A retrospective database query was performed to identify patients diagnosed with primary shoulder OA, excluding those with other shoulder pathologies. Patients were stratified according to prediagnosis GLP-۱RA prescription status and were ۱:۱ propensity-score matched to balance relevant comorbidities. Outcomes included the incidence of TSA, TSA-free survival assessed using Kaplan–Meier survival analysis, major joint injections, and mean levels of inflammatory biomarkers, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and cortisol. A significance threshold of P < ۰.۰۵ was applied. Results: After matching, each cohort included ۲۴,۶۶۹ patients. The GLP-۱RA cohort had a significantly shorter follow-up duration than the non-GLP-۱RA cohort (۷۳۱ ± ۶۹۴ vs. ۱,۲۲۰ ± ۱,۰۰۶ days; P < ۰.۰۰۱). TSA incidence was higher among GLP-۱RA users than among non-users (۲.۲۵% vs. ۱.۷۷%; P < ۰.۰۰۱), and TSA-free survival was lower in the GLP-۱RA cohort (۹۵.۵۰% vs. ۹۷.۲۳%; log-rank P < ۰.۰۰۱). A greater proportion of patients in the GLP-۱RA cohort received major joint injections (۱۸.۹۳% vs. ۱۶.۸۷%; P < ۰.۰۰۱), although the mean number of injections per patient was lower in this group (۲.۴۸ ± ۲.۸۶ vs. ۲.۷۴ ± ۳.۲۳; P < ۰.۰۰۱). GLP-۱RA users also demonstrated significantly lower mean CRP and ESR levels (both P < ۰.۰۰۱), while mean cortisol levels were similar between cohorts. Conclusion: In contrast to findings reported for hip and knee OA, GLP-۱RA use was not associated with a protective effect against progression to TSA in patients with primary shoulder OA. Further studies are warranted to clarify the joint-specific mechanisms that may underlie these differences. Level of evidence: III
کلیدواژه ها:
نویسندگان
مراجع و منابع این مقاله:
لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :